Literature DB >> 7249488

Altered plasma protein binding of drugs in thyroid disease.

J Feely, I H Stevenson, J Crooks.   

Abstract

The plasma protein binding of propranolol and warfarin was studied in vitro by ultrafiltration in hyper- and hypothyroid patients both before and after treatment. The degree of binding of propranolol was significantly decreased in hyperthyroid patients and increased in hypothyroid patients, and was negatively correlated with serum thyroxine and the free thyroxine index. The plasma protein binding of warfarin was also decreased in hyperthyroid patients, but was unchanged in hypothyroid patients. These results suggest that the binding of both acidic and basic drugs may be altered by thyroid disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7249488     DOI: 10.2165/00003088-198106040-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  31 in total

1.  THE BIOLOGICAL DISAPPEARANCE RATE OF PROTHROMBIN, FACTORS VII, IX AND X FROM PLASMA IN HYPOTHYROIDISM, HYPERTHYROIDISM, AND DURING FEVER.

Authors:  E A LOELIGER; B VAN DER ESCH; M J MATTERN; H C HEMKER
Journal:  Thromb Diath Haemorrh       Date:  1964-01-01

2.  Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling.

Authors:  M Wood; D G Shand; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

Review 3.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 4.  Protein binding of coumarin anticoagulants in disease states.

Authors:  K Bachmann; R Shapiro
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

5.  Increased plasma binding of quinidine after surgery: a preliminary report.

Authors:  D Fremstad; K Bergerud; J F Haffner; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

6.  Increased clearance of propranolol in thyrotoxicosis.

Authors:  J Feely; I H Stevenson; J Crooks
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

7.  The effect of various drugs on the binding of warfarin-14C to human albumin.

Authors:  H M Solomon; J J Schrogie
Journal:  Biochem Pharmacol       Date:  1967-07-07       Impact factor: 5.858

8.  The effects of dextrothyroxine on the kinetics of prothrombin activity: proposed mechanism of the potentiation of warfarin by D-thyroxine.

Authors:  M Weintraub; R T Breckenridge; P F Griner
Journal:  J Lab Clin Med       Date:  1973-02

9.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

10.  Simple solid-phase radioimmunoassays for total tri-iodothyronine and thyroxine in serum, and their clinical evaluation.

Authors:  J Seth; A D Toft; W J Irvine
Journal:  Clin Chim Acta       Date:  1976-05-03       Impact factor: 3.786

View more
  14 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 3.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

4.  Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism.

Authors:  Y Hashimoto; M Yasuhara; A Kamiya; K Okumura; R Hori
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

Review 5.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

8.  Oxazepam pharmacokinetics in thyroid disease.

Authors:  A K Scott; A S Khir; P D Bewsher; G M Hawksworth
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

9.  Evolution of atenolol kinetics when hypothyroidism is corrected.

Authors:  H Levesque; M O Richard; J Fresel; A Gancel; N Moore; H Courtois
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Serum protein binding of propylthiouracil.

Authors:  J P Kampmann; J E Mølholm Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.